Medtronic secures fda approval for the altaviva™ device, a simple experience for treating urge urinary incontinence

The implantable tibial neuromodulation (itnm) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks galway, ireland , sept. 19, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, announced today that it has received u.s. food and drug administration (fda) approval for the altaviva™ device.
MDT Ratings Summary
MDT Quant Ranking